I claim:

1. A composition ~~method~~ for use in a method for the prophylaxis or treatment of a dengue virus infection in a subject, ~~comprising administering a therapeutically effective amount of a~~ the composition containing at least one peptide or oligopeptide comprising or consisting of the amino acid sequence selected from ~~a~~ the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, ~~and~~ 17 and an active fragment of any one of sequences 1-17, wherein said peptide or oligopeptide amino acid sequence binds to class I MHC molecules to induce a cytotoxic T lymphocyte-mediated immune response.

2. The composition for use according to ~~method of~~ claim 1 further comprising a pharmaceutically acceptable carrier.

3. The composition for use according to~~method of~~ claim 2 wherein the pharmaceutically acceptable carrier is an adjuvant or at least one cytokine.

4. The method of claim 1 wherein said ~~composition is a~~ peptide comprises amino acid length is greater than about 14 up to about 30 to 40 amino acids in length~~, oligopeptide, or polypeptide containing said amino acid sequence~~.

5. The method of claim ~~4~~ 1 wherein said ~~composition contains said amino acid sequence obtained from a fragmented and processed peptide,~~ oligopeptide comprises amino acid of 8-14 amino acids in length~~, or polypeptide~~.

6. The composition for use according to ~~method of~~ claim 1 wherein said amino acid sequence comprises at least one T cell epitopic peptide.

7. The composition for use according to ~~method of~~ claim 1 wherein said ~~amino acid sequence~~functional fragment differs by no more than at least one amino acid from any one of amino acid sequences selected from SEQ ID NO: 1 ~~through~~ to 17.

8. The composition for use according to ~~method of~~ claim 7 where the one amino acid difference is a conservative amino acid substitution.

9. The composition for use according to ~~method of~~ claim 7 where the amino acid difference is a substitution of one hydrophobic amino acid with another hydrophobic amino acid.

10. The composition for use according to ~~method of~~ claim 1 wherein said cytotoxic T lymphocyte-mediated immune response is against at least one serotype specific dengue virus infection.

11. The composition for use according to ~~method of~~ claim 10 wherein said cytotoxic T lymphocyte-mediated immune response is against serotype specific dengue virus infections from a group consisting of serotype 1 , 2, 3, 4, and combinations thereof.

12. The composition for use according to ~~method of~~ claim 11 wherein said cytotoxic T lymphocyte-mediated immune response is against serotypes 1, 2, 3, and 4.

13. A ~~method~~ composition for use in a method of inducing a cytotoxic T lymphocyte-mediated immune response in a subject, said method comprising administering an effective amount of said composition, wherein the ~~a~~ composition ~~containing~~ contains at least one peptide or oligopeptide comprising or consisting of the amino acid sequence selected from ~~a~~ the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, ~~and~~ 17 and an active fragment of any one of sequences 1-17.

14. The method of claim 13 wherein said ~~composition is a~~ peptide comprises amino acid length is greater than about 14 up to about 30 to 40 amino acids in length~~, oligopeptide, or polypeptide containing said amino acid sequence~~.

15. The method of claim 14 wherein said ~~composition contains said amino acid sequence obtained from a fragmented and processed peptide,~~ oligopeptide comprises amino acid of 8-14 amino acids in length~~, or polypeptide~~.

16. The composition for use~~method of~~ according to claim 13 wherein said amino acid sequence comprises at least one epitopic peptide.

17. The composition for use~~method of~~ according to claim 13 wherein said functional fragment ~~amino acid sequence~~ differs by no more than at least one amino acid from any one of amino acid sequences selected from SEQ ID NO: 1 through 17.

18. The composition for use~~method of~~ according to claim 17~~,~~ wherein the one amino acid difference is a conservative amino acid substitution.

19. The composition for use~~method of~~according to claim 17 , wherein the amino acid difference is a substitution of one hydrophobic amino acid with another hydrophobic amino acid.

20. A dengue virus vaccine comprising a composition containing at least one peptide or oligopeptide comprising or consisting of the amino acid sequence selected from ~~a~~ the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, ~~and~~ 17 and an active fragment of any one of sequences 1-17.

21. A vaccine for use in a ~~-~~method of preventing disease caused by dengue virus in a subject, the method comprising administering an effective amount of ~~the~~ said vaccine ~~of claim 20~~ to the subject, wherein said vaccine is the vaccine of claim 20.

22. ~~A method of inducing in a subject an immune response to at least one dengue virus comprising administering to a subject in need thereof an amount of~~ a polynucleotide ~~effective to induce an immune response to at least one dengue virus serotype wherein said polynucleotide~~ sequence ~~encodes~~ encoding a peptide or ~~polypeptide~~ oligopeptide comprising or consisting of an amino acid sequence that has at least 95% sequence

identity to an amino acid sequence selected from ~~a~~ the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17, wherein said peptide or oligopeptide amino acid sequence binds to class I MHC molecules to induce a cytotoxic T lymphocyte-mediated immune response, for use in a method of inducing in a subject an immune response to at least one dengue virus, said method comprising administering to a subject in need thereof an amount of said polynucleotide effective to induce an immune response to at least one dengue virus serotype.